Last updated: April 23, 2026
Which suppliers are active for labetalol hydrochloride (drug substance)?
The market for labetalol hydrochloride is supplied by established generics and chemical manufacturers spanning China, India, Europe, and North America. The most reliable path to verified supply is typically through drug substance (API) suppliers that hold or support DMF submissions in major jurisdictions and can supply auditable quality documentation (CoA, GMP status, impurity profiles).
Because “supplier” can mean multiple categories (API makers, intermediate makers, salt-formulation packers, or finished-dose manufacturers), only suppliers that can support labetalol hydrochloride as an API or as an explicitly labeled chemical supply are relevant for procurement.
Supplier categories to target (procurement-ready)
- API manufacturers of labetalol hydrochloride (drug substance)
- DMF-holding companies supplying labetalol HCl to generics
- Chemical distributors reselling labetalol hydrochloride with batch traceability
- Finished-dose manufacturers (tablets/IV product) if sourcing at dose level is acceptable
Which firms commonly supply labetalol hydrochloride in global pharma supply chains?
Below are supplier names that are consistently referenced across global generics and API supply ecosystems for labetalol and labetalol salts. This list is intended for business sourcing and due diligence workflows (DMF/GMP verification first, then commercial quotes).
API and chemical supply firms (global)
- Aurobindo Pharma (API and generics; labetalol products and/or upstream API supply lines in global portfolio)
- Mylan / Viatris (generics; labetalol product supply presence in major markets)
- Teva (generics; labetalol product supply presence in major markets)
- Sun Pharma (generics; labetalol product supply presence in major markets)
- Cipla (generics; labetalol product supply presence in major markets)
Specialty chemical and API manufacturing firms (typical API sourcing set)
- Hetero Labs (API manufacturing footprint for cardiovascular drugs)
- Dr. Reddy’s Laboratories (API manufacturing footprint; cardiovascular portfolio)
- Cadila (Zydus Cadila) (generics and API ecosystem; cardiovascular portfolio)
- Biocon (selected API manufacture portfolio; generally active in global supply networks)
- Nectar Life Sciences (bulk pharma chemicals and API supply channels)
Practical procurement note: for labetalol hydrochloride, sourcing is usually executed as “API bulk supply” or “chemical bulk supply” under a specified grade (e.g., USP/EP), with compliance documents aligned to target markets.
Which supplier due-diligence checks reduce procurement and compliance risk?
For labetalol hydrochloride, contracts fail most often on documentation mismatch (grade, specification, polymorph/solid form control, residual solvents, elemental impurities, and route-related impurities). Procurement should gate on the following:
Quality and compliance gates
- DMF or relevant regulatory dossier support for the target region (US FDA DMF, EU ASMF, UK variant support)
- GMP certificate (site-level, batch-level traceability)
- Specification alignment to target compendial standard (commonly USP or EP grade alignment depending on market)
- CoA completeness: identity, assay, impurities (total and individual), water content if applicable
- Residual solvents: meets ICH Q3C thresholds for likely solvents used in manufacturing
- Elemental impurities: meets ICH Q3D limits
- Stability and retest policy: shelf life, storage conditions, retest interval
What intermediates and salt-form inputs matter for labetalol hydrochloride supply?
Labetalol hydrochloride is a salt form. Procurement may require visibility into salt formation and drying steps. In practice, suppliers manage two core upstream input streams:
Upstream manufacturing inputs to confirm
- Labetalol base (the free base) quality and impurity control
- Hydrochloric acid (HCl) used for salt formation, typically specifying grade and any contaminants
Key process controls procurement should demand
- Salt formation conditions that control impurity carryover
- Drying endpoint and solid form control
- Control of process-related impurities that can shift during conversion from base to HCl salt
Which finished-dose manufacturers are direct alternatives if API supply is constrained?
If the requirement is practical supply continuity (rather than API-only), direct finished-dose procurement can reduce supplier fragmentation.
Finished-dose suppliers with market presence
- Lupin (US/EU generics presence)
- Dr. Reddy’s (generics presence)
- Teva
- Mylan / Viatris
- Sandoz (Novartis generics distribution footprint)
- Cipla
How to structure RFQs for labetalol hydrochloride to force apples-to-apples bids
RFQs should force bidders to provide structured quality evidence and commercial readiness:
RFQ fields that should be mandatory
- Grade (USP/EP or in-house spec) and target CoA template
- Batch size and lead time to first supply
- GMP site and whether DMF/ASMF is available for the target region
- Impurity list and limit strategy (total impurities and top specified impurities)
- Solvent system and residual solvent compliance statement
- Storage conditions and retest/shelf-life commitments
- Packaging (drums/bags, nitrogen backfill if used) and sample retention policy
Key Takeaways
- Labetalol hydrochloride supply typically comes from API manufacturers with dossier support plus global generics that provide alternative purchasing at dose level.
- Procurement should prioritize suppliers that can deliver DMF/GMP-backed documentation and provide CoA impurity transparency, residual solvents compliance, and retest policy.
- If API lead times or documentation block progress, finished-dose procurement from major generics can preserve market continuity while sourcing the API in parallel.
FAQs
-
What documents matter most when sourcing labetalol hydrochloride API?
GMP certificate for the manufacturing site, CoA aligned to the requested grade, and DMF/ASMF support for the destination market.
-
Is labetalol hydrochloride sourced from multiple chemical grades?
Yes. Suppliers typically sell labetalol HCl under specific grade standards (often USP/EP-aligned). Procurement should lock the grade in the RFQ.
-
What are the main quality risks for labetalol hydrochloride salts?
Impurity carryover from the labetalol base, salt formation process impurities, and residual solvent plus elemental impurity compliance.
-
If API sourcing is delayed, can finished-dose sourcing substitute?
Yes. Major generics with labetalol product presence can reduce continuity risk, but this shifts sourcing from API to dose-level supply.
-
What should RFQs require to compare suppliers fairly?
Grade/spec, impurity profile and limits, residual solvents, GMP site identity, lead time, batch size, and retest/shelf-life.
References
[1] USP Drug Substances and USP-NF (labetalol hydrochloride monographs and general chapters).
[2] European Pharmacopoeia (labetalol hydrochloride relevant monograph/specification guidance).
[3] ICH Q3C and ICH Q3D (residual solvents and elemental impurities quality standards).
[4] FDA DMF and ASMF framework (dossier support expectations for drug substance supply).
